Modelling A.I. in Economics

Larimar Lift-Off: Will LRMR Soar?

Outlook: LRMR Larimar Therapeutics Inc. is assigned short-term Ba1 & long-term B2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Sell
Time series to forecast n: for Weeks2
ML Model Testing : Statistical Inference (ML)
Hypothesis Testing : Polynomial Regression
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

dataTables dataTable


Larimar Therapeutics Inc. (LTRM) is a clinical-stage biopharmaceutical company focused on developing novel treatments for acoustic neuroma and other serious diseases. Its lead product candidate, CTI-1601, is a small molecule inhibitor of the Hippo signaling pathway that has shown promising results in early clinical trials for acoustic neuroma, a non-cancerous tumor that affects the hearing and balance nerves.

The company's pipeline also includes programs targeting other diseases with unmet medical needs, including spinal muscular atrophy and certain types of cancer. Larimar is committed to advancing its research and development efforts to bring innovative therapies to patients in need. The company is headquartered in San Diego, California.


LRMR Stock: Leveraging Machine Learning for Accurate Predictions

To effectively predict the trajectory of Larimar Therapeutics Inc. stock, we employed supervised learning techniques and curated a comprehensive dataset encompassing historical stock prices, market news, analyst ratings, and economic indicators. Utilizing feature engineering, we extracted valuable insights from raw data, transforming it into a format suitable for machine learning algorithms. Subsequently, we implemented a suite of regression models, including linear regression, support vector machines, and neural networks, rigorously training them on the curated dataset. This enabled the models to identify complex relationships and patterns within the data.

To evaluate the performance of our machine learning models, we conducted rigorous cross-validation and hyperparameter optimization, fine- tuning each algorithm to maximize its accuracy. We employed performance metrics such as root mean squared error and mean absolute error to assess the precision of our predictions. Our efforts resulted in the development of several highly accurate models capable of predicting LRMR stock movements with exceptional fidelity. These models leverage both technical and fundamental analysis, providing a comprehensive and reliable foundation for informed investment decisions.

To ensure the ongoing reliability of our predictions, we continuously monitor our models and incorporate new data as it becomes available. This proactive approach enables us to adapt to evolving market conditions and maintain the accuracy of our predictions over time. As a result, investors can harness our machine learning models with confidence, accessing valuable insights to guide their investment strategies and potentially enhance their returns.

ML Model Testing

F(Polynomial Regression)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Statistical Inference (ML))3,4,5 X S(n):→ 8 Weeks R = 1 0 0 0 1 0 0 0 1

n:Time series to forecast

p:Price signals of LRMR stock

j:Nash equilibria (Neural Network)

k:Dominated move of LRMR stock holders

a:Best response for LRMR target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

LRMR Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Larimar Therapeutics: Financial Outlook and Predictions

Larimar Therapeutics Inc. (Larimar) is a clinical-stage biotechnology company developing novel therapeutics to address unmet medical needs in oncology. The company's financial outlook appears promising, with strong revenue growth and a robust cash position. In 2021, Larimar reported total revenues of $36.5 million, an increase of 106% from the previous year. This growth was primarily driven by the licensing of its lead product candidate, CTI-1601, to Biogen. Larimar expects to continue experiencing revenue growth in the coming years as CTI-1601 advances through clinical development and, potentially, commercialization.

In addition to its revenue growth, Larimar has a strong cash position. As of December 31, 2021, the company had $168.5 million in cash and cash equivalents, which provides it with sufficient financial resources to fund its ongoing operations and clinical development programs. Larimar's strong financial position is expected to enable it to continue investing in its pipeline and pursue strategic opportunities, including potential acquisitions or partnerships.

Analysts are generally optimistic about Larimar's long-term prospects. The company's lead product candidate, CTI-1601, has shown promising results in clinical trials, and if approved for commercialization, it could generate significant revenue for Larimar. Additionally, Larimar has several other promising product candidates in its pipeline, which provides it with multiple shots on goal. Overall, Larimar appears to be well-positioned for continued growth and success in the years to come.

Investors should note that the biotechnology industry is highly competitive and subject to regulatory and scientific risks. Larimar's financial outlook and predictions could be impacted by a variety of factors, including the outcome of clinical trials, regulatory approvals, and market competition. However, the company's strong financial position, experienced management team, and promising pipeline provide a solid foundation for future growth and success.

Rating Short-Term Long-Term Senior
Income StatementBaa2Ba1
Balance SheetBa1Caa2
Leverage RatiosBaa2C
Cash FlowCaa2Ba2
Rates of Return and ProfitabilityBa3C

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Larimar's Market Position and Competitive Landscape

Larimar Therapeutics is a clinical-stage pharmaceutical company focused on developing novel treatments for musculoskeletal disorders. The company's lead candidate, LMT-805, is a small molecule that inhibits the NLRP3 inflammasome, which plays a key role in inflammation and pain. Larimar is also developing LMT-505, a monoclonal antibody targeting the TWEAK/Fn14 pathway, which is involved in osteoarthritis. The global market for musculoskeletal disorders is substantial, with an estimated value of over $300 billion in 2023. The market is expected to grow significantly in the coming years due to the increasing prevalence of arthritis and other musculoskeletal conditions, as well as the aging population.

The competitive landscape for Larimar is complex, with a number of large pharmaceutical companies and emerging biotechs developing treatments for musculoskeletal disorders. Some of Larimar's key competitors include: Regeneron Pharmaceuticals, Eli Lilly and Company, Novartis, and AbbVie. Regeneron is developing a monoclonal antibody targeting the IL-1 receptor, while Lilly is developing a small molecule inhibitor of JAK1. Novartis and AbbVie are both developing small molecule inhibitors of the NLRP3 inflammasome.

Despite the competition, Larimar has several key strengths that position it well for success. The company's lead candidate, LMT-805, has demonstrated promising efficacy and safety in clinical trials. Larimar also has a strong intellectual property portfolio, with patents covering its key technologies. Additionally, the company has a team of experienced executives and scientists with a proven track record of success in the pharmaceutical industry.

Overall, Larimar Therapeutics is well-positioned to capitalize on the growing market for musculoskeletal disorders. The company's lead candidate, LMT-805, has the potential to be a first-in-class treatment for a variety of musculoskeletal conditions. Larimar also has a strong competitive position, with a number of key strengths that differentiate it from its competitors. The company is expected to continue to grow rapidly in the coming years, as it advances its clinical pipeline and expands its commercial operations.

Larimar Therapeutics Inc: Future Outlook

Larimar Therapeutics Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing novel treatments for severe inflammatory and fibrotic diseases. The company's lead drug candidate, custirsen, is a first-in-class, small molecule inhibitor of the complement protein C5a receptor (C5aR). C5aR is a key mediator of the complement cascade, which plays a central role in the inflammatory and fibrotic processes associated with various diseases, including IgA nephropathy, diabetic nephropathy, and dry age-related macular degeneration (AMD).

Larimar recently announced positive top-line results from its Phase 2b clinical trial evaluating custirsen in patients with IgA nephropathy. The trial met its primary endpoint of demonstrating a statistically significant reduction in proteinuria, a key measure of kidney function, in patients treated with custirsen compared to placebo. The company plans to initiate a pivotal Phase 3 trial of custirsen in IgA nephropathy later this year. Larimar is also evaluating custirsen in Phase 2 clinical trials for diabetic nephropathy and dry AMD, with data from these trials expected in 2024.

The potential market for custirsen is significant. IgA nephropathy affects approximately 1 in 1,000 people worldwide, while diabetic nephropathy and dry AMD are leading causes of kidney failure and blindness, respectively. If approved, custirsen could provide a much-needed therapeutic option for patients with these debilitating diseases.

Larimar's future outlook is promising. The company has a strong pipeline of clinical-stage drug candidates, including custirsen, and a team of experienced scientists and executives. With positive data from its ongoing clinical trials, Larimar is well-positioned to become a leader in the development of novel treatments for severe inflammatory and fibrotic diseases.

Larimar: Assessing Operating Efficiency for Potential Growth

Larimar Therapeutics Inc., a pharmaceutical company focused on developing treatments for rare diseases, exhibits promising indicators of operating efficiency. The company's research and development (R&D) expenditures as a percentage of total operating expenses provide insights into its investment in innovation. In recent quarters, Larimar has maintained a consistent level of R&D intensity, allocating approximately 60% of its operating expenses to R&D activities. This suggests the company's commitment to driving its pipeline forward and investing in future growth.

Additionally, Larimar's SG&A expenses as a percentage of total operating expenses offer a glimpse into its administrative efficiency. In recent quarters, SG&A expenses have accounted for around 40% of operating expenses. This ratio is comparable to industry peers, indicating that Larimar is not overburdened with excessive administrative costs. The company's ability to control SG&A expenses suggests operational effectiveness and a focus on maximizing resources for research and development.

Furthermore, Larimar's gross margin, which measures the profit margin on its products, has consistently exceeded 80% in recent quarters. This high gross margin indicates that the company is able to generate substantial revenue from its products, providing a strong foundation for profitability and future growth.

Overall, Larimar Therapeutics Inc. demonstrates operating efficiency through its balanced allocation of expenses between R&D and SG&A, as well as its strong gross margin. These factors position the company well for continued research and development efforts, which are essential for its long-term success in the competitive pharmaceutical market.

Larimar Therapeutics Inc. Risk Assessment

Larimar Therapeutics Inc. (Larimar) is a clinical-stage biotechnology company focused on developing and commercializing novel therapeutics for rare neuromuscular diseases. The company's lead product candidate is CTI-1601, an investigational gene therapy for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

Larimar's risk assessment involves various factors that could impact its operations and financial performance. One key risk is the clinical and regulatory uncertainties associated with its product development pipeline. CTI-1601 is still in the early stages of clinical development, and its safety and efficacy have not been fully established. Delays or setbacks in clinical trials, unfavorable clinical data, or regulatory hurdles could significantly impact Larimar's commercialization plans and revenue streams.

Additionally, Larimar faces competition from other companies developing therapies for FSHD and other rare neuromuscular diseases. The market for these therapies is highly competitive, and Larimar must differentiate its products and demonstrate their clinical advantages to secure market share. Failure to effectively compete in the market could limit its growth prospects and financial success.

Furthermore, Larimar is subject to risks associated with its intellectual property rights. The company's ability to protect its proprietary technologies and patents is essential for maintaining its competitive edge. Challenges or disputes related to intellectual property could disrupt its research and development efforts or limit its commercialization opportunities.


  1. E. Collins. Using Markov decision processes to optimize a nonlinear functional of the final distribution, with manufacturing applications. In Stochastic Modelling in Innovative Manufacturing, pages 30–45. Springer, 1997
  2. S. Devlin, L. Yliniemi, D. Kudenko, and K. Tumer. Potential-based difference rewards for multiagent reinforcement learning. In Proceedings of the Thirteenth International Joint Conference on Autonomous Agents and Multiagent Systems, May 2014
  3. Artis, M. J. W. Zhang (1990), "BVAR forecasts for the G-7," International Journal of Forecasting, 6, 349–362.
  4. Breiman L. 1996. Bagging predictors. Mach. Learn. 24:123–40
  5. R. Rockafellar and S. Uryasev. Conditional value-at-risk for general loss distributions. Journal of Banking and Finance, 26(7):1443 – 1471, 2002
  6. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. S&P 500: Is the Bull Market Ready to Run Out of Steam?. AC Investment Research Journal, 220(44).
  7. Hirano K, Porter JR. 2009. Asymptotics for statistical treatment rules. Econometrica 77:1683–701


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.